The Canadian Institutes of Health Research (CIHR) recently announced the results of the latest "Project Grant" competition. Six researchers from the CRC, whose innovative projects were selected, will receive substantial financial support. The CRC warmly congratulates these teams for the originality and significance of their work, which illustrates the dynamism and richness of research within the center.
Yohan Bossé: The lung molecular and cellular transition to adenocarcinoma
This project aims to deepen the understanding of the molecular and cellular transitions leading to lung adenocarcinoma, paving the way for new prevention and treatment strategies.
Humphrey Fonge: Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC
This innovative project focuses on developing GMP-grade radioimmunoconjugates targeting Nectin-4 and conducting preclinical studies for a phase 1 clinical trial against Nectin-4 positive non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Anne Gangloff: Early cholesterol blockade in advanced pancreatic cancer
This research explores the impact of early cholesterol blockade in the treatment of advanced pancreatic cancer, with the goal of opening new therapeutic avenues.
Lynn Gauthier: MI SENS-OR REHAB: Feasibility, acceptability, and preliminary effects of a novel, multimodal, Motivational Interviewing-guided somatoSENSory - motOR REHABilitation intervention for chemotherapy-induced peripheral neuropathy
The MI SENS-OR REHAB project evaluates the feasibility and preliminary effects of a novel, multimodal, motivational interviewing-guided sensorimotor rehabilitation intervention for chemotherapy-induced peripheral neuropathy.
Tom Moss: The Ribosomal RNA Genes in the Control of Growth, Pluripotency, Senescence and Cancer
This fundamental study analyzes the role of ribosomal RNA genes in the regulation of growth, pluripotency, senescence, and cancer.
Paul Toren: Repurposing 5-alpha reductase inhibitors to improve outcomes for bladder cancer patients
This project aims to repurpose 5-alpha reductase inhibitors to improve the prognosis of bladder cancer patients.
Once again, the CRC congratulates them for their contribution!